Entry Rationale
It is judged that a phased buying strategy remains valid, as the stock is located near the support level of $8.16, which is its recent 20-day low.
Solid Biosciences wins new Outperform at RBC on DMD opportunity
Solid Biosciences has received a new 'Outperform' rating from RBC, driven by its Duchenne muscular dystrophy (DMD) opportunity.
It is judged that a phased buying strategy remains valid, as the stock is located near the support level of $8.16, which is its recent 20-day low.
If the recent 20-day low support level of $8.16 is breached, I will cut losses, and I will take profits when it rebounds toward the 20-day high short-term resistance level of $10.48.
At the entry point, technical indicators show the RSI(14) at 31.5, nearing the oversold zone; moving averages are in a bullish alignment (short-term above long-term); trading volume is 1.79 times the 20-day average; and the volatility over the past 7 days recorded -19.7%.
Based on RBC's 'Outperform' rating and the support level near the recent 20-day low of $8.16, a phased buying approach was taken, but the actual result was a FAILED verdict with an 11.1% loss (-11.1% return). At the time of entry, the RSI (14) was 31.5, nearing the oversold zone, and volume flowed in at 1.79 times the 20-day average. However, it failed to defend against the downward volatility of -19.7% over the past 7 days and ultimately closed below the stop-loss line of $8.16.
Even with an increasing trend in thematic news and positive analyst reports, amid the strong downward volatility (-19.7%) over the past 7 days, additional downward pressure must be evaluated more conservatively, even near support levels. In future trading, rather than immediately initiating scaled-in purchases upon reaching technical support lines, a filter will be added to confirm that downside momentum has subsided and candle patterns have stabilized, thereby managing stop-loss risks.